MedTrace Logo

Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer

NCT01666977 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2016-06-03

No results posted yet for this study

Summary

The purpose of this phase 1b/2 study is to estimate the treatment effect of study drug measuring progression free survival.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

AMG 386

15mg/kg

DRUG

AMG 386

30 mg/kg

DRUG

AMG 386 Placebo

AMG 386 Placebo

DRUG

Pemetrexed

Pemetrexed 500 mg/m2

DRUG

Carboplatin

Carboplatin AUC 6

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Greece
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01666977 on ClinicalTrials.gov